Believe in possibilities BUILDING BETTER BIOLOGICS™ We believe we have a unique opportunity to use our combined talents to achieve something bigger than ourselves. Together, we can shape new possibilities for patients everywhere. Zymeworks Inc. is a publicly listed (NYSE: ZYME), clinical-stage, biopharmaceutical company dedicated to the discovery, development, and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer. Zymeworks’ suite of complementary therapeutic platforms and its fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated product candidates. Zymeworks’ lead product candidate, zanidatamab, is a HER2-targeted bispecific antibody developed using Zymeworks proprietary Azymetric™ platform. Zanidatamab is currently being evaluated in global Phase 1, Phase 2, and pivotal clinical trials as a best-in-class treatment for patients with HER2-expressing cancers, including biliary tract, gastroesophageal adenocarcinomas, breast, and other tumor types. Zymeworks’ second candidate, ZW49, is a HER2-targeted antibody drug conjugate (ADC) developed using Zymeworks’ proprietary Azymetric™ and ZymeLink™ platforms. ZW49 is currently being evaluated in a Phase 1 clinical trial as a treatment for patients with HER2-expressing cancers. Zymeworks is also advancing a deep pipeline of preclinical product candidates and discovery-stage programs in oncology (including immuno-oncology agents) and other therapeutic areas. In addition to Zymeworks’ wholly owned pipeline, its therapeutic platforms have been further leveraged through strategic partnerships with global biopharmaceutical companies. LEADERSHIP Ali Tehrani PhD President & CEO Neil Klompas CPA, CA EVP, Business Operations & CFO Neil Josephson MD Chief Medical Officer Tony Polverino PhD EVP, Early Development & CSO Kathryn O'Driscoll Chief People Officer James Priour MBA Chief Commercial Officer BOARD OF DIRECTORS Lota Zoth CPA Chair of the Board Troy Cox MBA Director Kenneth Hillan MB, CHB Director Sue Mahony PhD MBA Director Kelvin Neu MD Director Hollings C Renton MBA Director Natalie Sacks MD Director Ali Tehrani PhD Director TECHNOLOGY Azymetric™ ZymeLink™ EFECT™ ProTECT™ Science PIPELINE Zanidatamab ZW49 Preclinical Candidates Partnerships Publications For Patients INVESTORS Stock Info News Releases Events & Presentations Financials Governance CORPORATE Leadership Board of Directors Careers Legal Privacy Contact Twitter LinkedIn